xdr

An antibiotic produced by Streptomyces fradiae.

Baxdrostat is an aldosterone synthase inhibitor.

(S)-Baxdrostat is an S-enantiomer of Baxdrostat, which functions as an inhibitor of aldosterone synthase [1].

oxdralazine is a useful organic compound for research related to life sciences. The catalog number is T68121 and the CAS number is 17259-75-5.

GSK2556286 (GSK286) is an orally active inhibitor of Mycobacterium tuberculosis (M. tuberculosis), effective against multidrug-resistant (MDR), extensively drug-resistant (XDR), and drug-sensitive (DS) strains. It inhibits the growth of human macrophages with an IC50 value of 0.07 μM.

Fosfomycin sodium is a bactericidal, low-molecular weight, broad-spectrum antibiotic, with putative activity against several bacteria, including multidrug-resistant Gram-negative bacteria, by irreversibly inhibiting an early stage in cell wall synthesis.

Fosfomycin calcium (Phosphomycin calcium salt) is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis.

Polymyxin B is a polymyxin antibiotic with antimicrobial activity that acts by binding with high affinity to the LPS of the bacterial wall and by increasing the permeability of the bacterial cell membrane, and is used in the study of infections caused by drug-resistant (XDR) Gram-negative bacteria (GNB) Polymyxin B is used in the study of endotoxemia.

Q-203 Ditosylate, also known as Q-203, is a mycobacterium tuberculosis protein potentially for the treatment of tuberculosis. The optimized IPA compound Q203 inhibited the growth of MDR and XDR M. tuberculosis clinical isolates in culture broth medium in

Mtb-IN-10 (Compound P15) is an Rv1625c Cya activator that influences the growth of Mycobacterium tuberculosis (Mtb) by modulating cAMP metabolism. It demonstrates an anti-tuberculosis activity with an EC50 of 1.96 µM in Mtb-infected macrophage models and achieves an oral bioavailability of 58.0% when administered orally to mice at 20 mg kg. Mtb-IN-10 potentially regulates intracellular signaling and disrupts cholesterol metabolism within Mtb, thereby inhibiting bacterial proliferation. It holds promise for tuberculosis (TB) research, particularly targeting multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains of Mtb.

K11, an antimicrobial peptide, demonstrates activity against MDR XDR K. pneumoniae isolates (MIC: 8-512 μg mL) and inhibits bacterial biofilm formation. It also acts synergistically with various antibiotics (Chloramphenicol, Meropenem, Rifampicin, etc.) to combat drug-resistant K. pneumoniae and exhibits high thermal and wide pH stability [1].

DprE1-IN-9 (compound B18) is an efficient, reversible inhibitor of DprE1, interacting with the enzyme's receptor cavity. It exhibits potent antimycobacterial properties, demonstrating activity against non-pathogenic H37Ra (MIC=0.18 µg mL) and pathogenic strains, including H37Rv, as well as clinical MDR and XDR isolates [1].

Antitubercular agent-47 (compound 5C) exhibits potent activity against tuberculosis and is effective against DS MDR XDR clinical isolates.